Navigation Links
AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Date:11/13/2008

ntaris signed a definitive agreement to sell to Cowen Healthcare Royalty Partners, L.P. ("CHRP") its rights to royalties on future sales of Cetrotide(R) covered by its license agreement with Merck Serono. The license agreement between AEterna Zentaris and Merck Serono was signed in 2000 and granted Merck Serono exclusive rights to market, distribute and sell Cetrotide worldwide, with the exception of Japan, in the field of in vitro fertilization. On closing, AEterna Zentaris will receive $52.5 million from CHRP. In addition, contingent on 2010 net sales of Cetrotide(R) reaching a specified level, AEterna Zentaris would receive an additional payment of $2.5 million from CHRP.

Under the terms of the agreement, if cetrorelix which is currently in Phase 3 clinical trials for the treatment of benign prostatic hyperplasia, is approved for sale by the European regulatory authorities in an indication other than in vitro fertilization, AEterna Zentaris has agreed to make a one-time cash payment to CHRP for an amount ranging from $5 million up to a maximum of $15 million. The amount which would be due to CHRP will be higher the earlier the product receives European regulatory approval.

"We are very pleased with the Cowen Healthcare Royalty Partners transaction for Cetrotide(R) which is in line with our strategy of generating non-dilutive financing. With this transaction, we strengthened our financial position to focus on the development of cetrorelix in BPH, while pursuing partnership opportunities for its future commercialization," said Juergen Engel, Ph.D., President and Chief Executive Officer of AEterna Zentaris. "At the drug development level, both our Phase 3 program in BPH with cetrorelix, and our Phase 2 program with our lead oncology compound, AEZS-108 in ovarian and endometrial cancer, met their recruitment goals as scheduled and remain on track. First results for cetrorelix in BPH are still expected in the third quarter of 2009, while those for AEZS-1
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
2. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
4. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
5. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
6. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
8. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
9. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
10. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
11. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
(Date:12/19/2014)... 2014 Charm Sciences is pleased to ... Detection of Aflatoxin M1 in raw commingled milk is ... party validation. The peer reviewed report of the validation ... for Agricultural and Fisheries Research (ILVO-T&V) has been published ... B1, the most toxic aflatoxin and a known carcinogen, ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... politics aside, every biologist knows that men and women truly ... area where those differences come to the fore: around 80 ... Social play behaviors also differ greatly between the sexes - ... girls. , ,Early in human development, critical brain proteins known ...
... The life sciences company Promega announced on Tuesday a ... that had been pending before the U.S. District Court ... Promega will hold a worldwide non-exclusive license from Benitec ... DNA-directed RNA interference (ddRNAi) technology. Promega will also receive ...
... an online provider of digital sheet music, announced on Tuesday ... Group to provide Word Music's collection of Christian music on ... , ,Word Music, a division of Warner Music Group based ... music from Christian songwriters such as Amy Grant, Point Of ...
Cached Biology Technology:Gender hormones may lend to social disorder therapies 2
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... July 2012, Apple introduced the fingerprint reading feature ... only device of Apple incorporating such a feature, ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... , This release is available in ... discovered a mechanism that helps to explain resilience ... work. The new findings, in the reward circuit ... high tech dragnet for compounds that boost the ...
... Researcher in the University of Bristol,s School of Biological Sciences ... as a cue to find coral reefs, but was amazed ... larvae which must quickly find a safe place to ... can do the same thing. The team designed a ...
... For years, researchers have known that resistance exercise training ... another force can be one of the most effective ... But many older people are unable to get the full ... as arthritis that prevent them from lifting enough weight to ...
Cached Biology News:Resilience factor low in depression, protects mice from stress 2Resilience factor low in depression, protects mice from stress 3Muscle mass in elderly boosted by combining resistance exercise and blood flow restriction 2